{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:04:31Z","timestamp":1793898271435,"version":"4.8.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023970","name":"LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023970","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Evaluate the efficacy and safety of guselkumab, an IL-23p19-subunit inhibitor, in a phase 2, multicentre, randomized, double-blind, placebo-controlled study of patients with active LN.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults (18\u201375\u2009years) with active LN [Class III\u2013IV proliferative nephritis (kidney biopsy) and urine protein-to-creatinine ratio (UPCR) of \u22651\u2009mg\/mg despite standard-of-care therapy] were randomized (1:1; planned sample\u2009=\u200960) to receive i.v. infusions of guselkumab 400\u2009mg or placebo at weeks 0, 4 and 8, then s.c. injections (guselkumab 200\u2009mg or placebo) at week 12 and every 4\u2009weeks through week 48 in addition to their background therapy. The primary endpoint was achievement of \u226550% decrease in proteinuria from baseline at week 24. Major secondary endpoints (week 24) were achievement of complete renal response (CRR), sustained reduction in steroid dose (\u226410\u2009mg\/day prednisone\/equivalent) from weeks 16\u201324, UPCR &amp;lt;0.5\u2009mg\/mg; &amp;lt;0.75\u2009mg\/mg, time to achieving CRR, and time to treatment failure. Safety was assessed through the end of the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Following enrolment challenges (COVID-19 pandemic; Ukraine\/Russia crisis), the sponsor terminated the study early; 33 participants were randomized (placebo, n\u2009=\u200916; guselkumab, n\u2009=\u200917). At week 24, 56.3% (9\/16) in the placebo group and 35.3% (6\/17) in the guselkumab group achieved the primary endpoint. No apparent differences were observed in the secondary endpoints. Through end-of-study, 75% of placebo patients and 71% of guselkumab patients reported \u22651 adverse event; most were of mild-to-moderate severity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Guselkumab+background therapy did not demonstrate superior reduction in proteinuria vs placebo+background therapy in this small cohort of patients with active LN. Safety results were consistent with the known safety profile of guselkumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov: NCT04376827.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae647","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T11:31:22Z","timestamp":1734175882000},"page":"2731-2740","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-2956","authenticated-orcid":false,"given":"Hans-Joachim","family":"Anders","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine IV, Hospital of the Ludwig-Maximilians University , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3495-4051","authenticated-orcid":false,"given":"Tak Mao","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine at the University of Hong Kong , Hong Kong,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Sanchez-Guerrero","sequence":"additional","affiliation":[{"name":"Departmento de Inmunolog\u00eda y Reumatolog\u00eda, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran , Mexico City,","place":["Mexico"]},{"name":"Sinai Health System and University Health Network, Division of Rheumatology, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wofsy","sequence":"additional","affiliation":[{"name":"University of California San Francisco , San Francisco, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bensley","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , Spring House, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilianne","family":"Kim","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , Spring House, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Hung","family":"Lo","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , Spring House, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathye","family":"Shu","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , Spring House, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shao","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , Spring House, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan S","family":"Karyekar","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , Spring House, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3250-3804","authenticated-orcid":false,"given":"Betty","family":"Diamond","sequence":"additional","affiliation":[{"name":"The Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases, The Feinstein Institutes for Medical Research , Manhasset, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"2025050316122402400_keae647-B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025050316122402400_keae647-B2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.amjmed.2004.04.029","article-title":"Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus","volume":"117","author":"Mok","year":"2004","journal-title":"Am J Med"},{"key":"2025050316122402400_keae647-B3","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/art.38006","article-title":"Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus","volume":"65","author":"Mok","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025050316122402400_keae647-B4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/jalm\/jfac036","article-title":"A review of lupus nephritis","volume":"7","author":"Alforaih","year":"2022","journal-title":"J Appl Lab Med"},{"key":"2025050316122402400_keae647-B5","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0961203320932219","article-title":"Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression","volume":"29","author":"Mahajan","year":"2020","journal-title":"Lupus"},{"key":"2025050316122402400_keae647-B6","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/biomedicines10061409","article-title":"A histology-guided approach to the management of patients with lupus nephritis: are we there yet?","volume":"10","author":"Obri\u0219c\u0103","year":"2022","journal-title":"Biomedicines"},{"key":"2025050316122402400_keae647-B7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"2025050316122402400_keae647-B8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of lupus nephritis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"2025050316122402400_keae647-B9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/art.40729","article-title":"All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014","volume":"71","author":"Jorge","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025050316122402400_keae647-B10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1136\/annrheumdis-2017-212732","article-title":"Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis","volume":"77","author":"Moroni","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025050316122402400_keae647-B11","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025050316122402400_keae647-B12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/ndt\/gfad230","article-title":"EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association-Immunonephrology Working Group (ERA-IWG) perspective","volume":"39","author":"Frangou","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025050316122402400_keae647-B13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025050316122402400_keae647-B14","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/ndt\/gft201","article-title":"Severe lupus nephritis: the predictive value of a \u226550% reduction in proteinuria at 6 months","volume":"28","author":"Korbet","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2025050316122402400_keae647-B15","year":"2021"},{"key":"2025050316122402400_keae647-B16","year":"2021"},{"key":"2025050316122402400_keae647-B17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"2025050316122402400_keae647-B18","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"2025050316122402400_keae647-B19","first-page":"1","article-title":"Significance of interleukin 23 in systemic lupus patients: relation to disease activity and damage indices","volume":"17","author":"Haroon","year":"2023","journal-title":"Biologics"},{"key":"2025050316122402400_keae647-B20","doi-asserted-by":"crossref","first-page":"9401432","DOI":"10.1155\/2017\/9401432","article-title":"Serum interleukin-23 in Polish patients with systemic lupus erythematosus: association with lupus nephritis, obesity, and peripheral vascular disease","volume":"2017","author":"Fischer","year":"2017","journal-title":"Mediators Inflamm"},{"key":"2025050316122402400_keae647-B21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/03009742.2014.962080","article-title":"Interleukin-27 and interleukin-23 in patients with systemic lupus erythematosus: possible role in lupus nephritis","volume":"44","author":"Xia","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"2025050316122402400_keae647-B22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12865-015-0070-7","article-title":"IL-17 and IL-23 in lupus nephritis\u2014association to histopathology and response to treatment","volume":"16","author":"Zickert","year":"2015","journal-title":"BMC Immunol"},{"key":"2025050316122402400_keae647-B23","doi-asserted-by":"crossref","first-page":"861028","DOI":"10.1155\/2013\/861028","article-title":"Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice","volume":"2013","author":"Kyttaris","year":"2013","journal-title":"Biomed Res Int"},{"key":"2025050316122402400_keae647-B24","year":"2024"},{"key":"2025050316122402400_keae647-B25","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41598-020-78972-1","article-title":"The ISN\/RPS 2016 classification predicts renal prognosis in patients with first-onset class III\/IV lupus nephritis","volume":"11","author":"Hachiya","year":"2021","journal-title":"Sci Rep"},{"key":"2025050316122402400_keae647-B26","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn\u2019s disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"2025050316122402400_keae647-B27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0961203309346505","article-title":"SLEDAI-2K for a 30-day window","volume":"19","author":"Touma","year":"2010","journal-title":"Lupus"},{"key":"2025050316122402400_keae647-B28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/0961203310385163","article-title":"SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation","volume":"20","author":"Touma","year":"2011","journal-title":"Lupus"},{"key":"2025050316122402400_keae647-B29","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/rheumatology\/ken208","article-title":"Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus\u2014results from LUMINA (LIX): a multiethnic US cohort","volume":"47","author":"Dur\u00e1n-Barrag\u00e1n","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316122402400_keae647-B30","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.jhh.1001761","article-title":"Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease","volume":"18","author":"Homma","year":"2004","journal-title":"J Hum Hypertens"},{"key":"2025050316122402400_keae647-B31","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.CIR.97.14.1411","article-title":"Angiotensin-converting enzyme inhibitors","volume":"97","author":"Brown","year":"1998","journal-title":"Circulation"},{"key":"2025050316122402400_keae647-B32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11906-017-0771-9","article-title":"Effects of RAAS inhibitors in patients with kidney disease","volume":"19","author":"Zhang","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"2025050316122402400_keae647-B33","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1191\/0961203305lu2249oa","article-title":"Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria","volume":"14","author":"Tse","year":"2005","journal-title":"Lupus"},{"key":"2025050316122402400_keae647-B34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1470320312474054","article-title":"Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials","volume":"15","author":"Geng","year":"2014","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2025050316122402400_keae647-B35","doi-asserted-by":"crossref","first-page":"e8575","DOI":"10.7717\/peerj.8575","article-title":"Comparative proteinuria management of different angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for normotensive patients with CKD: a Bayesian network meta-analysis","volume":"8","author":"Ye","year":"2020","journal-title":"PeerJ"},{"key":"2025050316122402400_keae647-B36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025050316122402400_keae647-B37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025050316122402400_keae647-B38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3899\/jrheum.220928","article-title":"Safety of guselkumab with and without prior tumor necrosis factor inhibitor treatment: pooled results across 4 studies in patients with psoriatic arthritis","volume":"50","author":"Rahman","year":"2023","journal-title":"J Rheumatol"},{"key":"2025050316122402400_keae647-B39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","article-title":"Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis","volume":"47","author":"Strober","year":"2024","journal-title":"Drug Saf"},{"key":"2025050316122402400_keae647-B40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00005792-199905000-00002","article-title":"Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center","volume":"78","author":"Huong","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"2025050316122402400_keae647-B41","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1371\/journal.pmed.0030396","article-title":"Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort","volume":"3","author":"Alarcon","year":"2006","journal-title":"PLoS Med"},{"key":"2025050316122402400_keae647-B42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/art.38238","article-title":"Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program","volume":"66","author":"Somers","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025050316122402400_keae647-B43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316122402400_keae647-B44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.berh.2018.09.004","article-title":"Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus","volume":"32","author":"Gergianaki","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025050316122402400_keae647-B45","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3899\/jrheum.111061","article-title":"Differences between male and female systemic lupus erythematosus in a multiethnic population","volume":"39","author":"Tan","year":"2012","journal-title":"J Rheumatol"},{"key":"2025050316122402400_keae647-B46","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1177\/0961203319856088","article-title":"Real-world electronic health record identifies antimalarial underprescribing in patients with lupus nephritis","volume":"28","author":"Xiong","year":"2019","journal-title":"Lupus"},{"key":"2025050316122402400_keae647-B47","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025050316122402400_keae647-B48","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae647\/60933585\/keae647.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2731\/60933585\/keae647.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2731\/60933585\/keae647.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:12:39Z","timestamp":1746303159000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/5\/2731\/7914939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,12,2]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae647","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,2]]}}}